Eric Pauwels

PTC Therapeutics CBO Eric Pauwels sells 21.3K shares at $75.00 for $1.6M under 10b5-1 plan

Eric Pauwels, Chief Business Officer of PTC Therapeutics, Inc., executed 2 separate sales totaling 21,277 shares for $1,595,775.00 at $75.00 per share on 2026-06-10 as part of a pre-arranged 10b5-1 trading plan adopted on 2026-02-25. Following this scheduled transaction, Pauwels retains 73,411 shares in non-derivative holdings, representing a -22.5% reduction from his pre-transaction position of 94,688 shares. The company reported revenue of $272,551,000.00 in its latest quarter with net income of $-2,809,000.00, and the stock currently trades at $75.14, within its 52-week range of $43.18–$87.50. Across his prior 5 sales at this same ticker, the 90-day returns after sale ranged from -14.4% to -11.4%, establishing a measurable historical pattern at this security.

Chief Business Officer Eric Pauwels sold 20,508 shares at $77.26 avg for $1.6M on 2025-12-19.

Pauwels executed 10 separate sales totaling 20,508 shares for $1,584,349.85 on a single date, reducing his holdings by 22.6% from 90,881 to 70,373 shares. The transaction is sizable in dollar terms and represents a material reduction in his shareholding. The stock is trading near 52-week highs (currently $77.70, within 9.9% of the $86.25 peak), and has appreciated 30.6% over the last 90 days, providing favorable exit pricing for the sale. However, his cross-ticker track record shows a 0.00% well-timed rate on 15 prior sells, and his 5 most recent same-ticker trades at PTCT (all within 2025-12-17 to 2025-12-18) lack measurable 30/90-day outcomes, providing limited historical context for evaluating the decision to sell at this juncture.

PTC Therapeutics CBO Pauwels sells 43,492 shares (~38.2% of holdings) for $3.3M amid -14.0% annual revenue decline

Pauwels Eric, Chief Business Officer at PTC Therapeutics, executed 8 separate sales totaling 43,492 shares for $3,279,275.05 (blended average $75.40) on 2025-12-17 and 2025-12-18, reducing his stake by 38.2% from 113,865 to 70,373 shares. The sale occurs against a backdrop of declining company fundamentals: annual revenue contracted 14.0%, and the company was unprofitable over its most recent full fiscal year. At current price of $78.57, the stock is 8.9% below its 52-week high, having gained 3.9% over 30 days and 29.9% over 90 days. The sale's size and timing—a substantial reduction of his open position—deserves investor scrutiny given the revenue headwinds and underlying profitability challenges, particularly since his cross-ticker track record shows a 0.00% well-timed rate on 17 prior sells (average 90-day return of +35.8%, indicating prior sales have typically been followed by stock appreciation).

PTC Therapeutics CBO Eric Pauwels sold 39,850 shares for $2,268,374.13 on 2025-09-08, reducing holdings by 35.3%

Eric Pauwels, Chief Business Officer of PTC Therapeutics, executed 7 separate sales totaling 39,850 shares for $2,268,374.13 at an average price of $56.92 on 2025-09-08. This reduces his holdings from 112,762 shares to 72,912 shares, a 35.3% reduction. The stock has appreciated 28.7% over the preceding 30 days and 15.0% over 90 days, putting the current price at $58.42, near the 52-week high of $58.42. Notably, the company is unprofitable (net income $-64.8M in the most recent quarter) with an annual revenue decline of 14.0%, suggesting the recent price appreciation may not yet reflect operational challenges. The magnitude and timing of this divestiture warrant monitoring of any material updates to company guidance or operational performance.